Experts discuss unique considerations related to HCV infection among persons with cancer. Topics include the rationale for HCV screening in persons with cancer; monitoring HCV-infected persons with cancer not receiving direct-acting antiviral (DAA) treatment; and timing and benefits of DAA therapy in relation to cancer treatment.